2026-10-19 15:09:18 UTC#481386newconfirmednews
BTIG reiterates Buy rating on Cullinan Therapeutics, maintains $40 price target
tradingviewimportance 0.30trust 0.60BTIG, LLC +0.20Cullinan Therapeutics, Inc. +0.50CLN-978 +0.50+2 entities
CGEM stock news
CGEM stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-02 10:32:22 UTC#404541newconfirmednews
HC Wainwright reiterates Buy on Cullinan Therapeutics, maintains $35 price target
tradingviewimportance 0.40trust 0.70Cullinan Therapeutics, Inc. +0.50H.C. Wainwright & Co., LLC 0Zipalertinib +0.50+1 entities
2026-10-02 10:13:00 UTC#404415duplicateconfirmednews
Cullinan Therapeutics begins FDA RTOR submission for zipalertinib in first-line NSCLC
tradingviewimportance 0.30trust 0.60Cullinan Therapeutics, Inc. +0.50Zipalertinib +0.50U.S. Food and Drug Administration +0.40+2 entities
2026-10-01 23:30:00 UTC#402434duplicateconfirmedpress release
Cullinan Therapeutics initiates FDA NDA submission for zipalertinib in first-line NSCLC
globenewswireimportance 0.40trust 1.00Cullinan Therapeutics, Inc. +0.60Zipalertinib +0.60U.S. Food and Drug Administration +0.20+2 entities
2026-10-01 23:30:00 UTC#402433newconfirmednews
Cullinan Therapeutics initiates FDA RTOR-based NDA for zipalertinib in first-line NSCLC
tradingviewimportance 0.60trust 0.70Cullinan Therapeutics, Inc. +0.60Zipalertinib +0.60Food and Drug Administration +0.40+1 entities
2026-09-25 11:58:00 UTC#368376newconfirmednews
HC Wainwright raises Cullinan Therapeutics (CGEM) price target to $35 from $30, maintains Buy
2026-09-25 09:59:00 UTC#367874newconfirmednews
BTIG maintains $40.00 price target on Cullinan Therapeutics (CGEM)
2026-09-24 18:45:26 UTC#364843updateconfirmednews
Cullinan Therapeutics (CGEM) details December CLN-978 data and pipeline progress for autoimmune programs
quartrimportance 0.40trust 0.60Cullinan Therapeutics, Inc. +0.30CLN-978 +0.30Velinotamig +0.20+2 entities
2026-09-24 16:37:46 UTC#364182newconfirmednews
Cullinan Therapeutics shares fall as company delays early-stage arthritis therapy trial data
2026-09-14 21:58:59 UTC#310398duplicateconfirmedanalysis
CG Oncology reiterates cretostimogene grenadenorepvec efficacy and upcoming pivotal trial catalysts
2026-09-14 21:41:46 UTC#310356newconfirmedanalysis
CG Oncology highlights cretostimogene efficacy and workflow advantages ahead of PIVOT-006 data
2026-09-14 17:24:00 UTC#309097newconfirmednews
BTIG raises Cullinan Therapeutics (CGEM) price target to $40.00 from $39.00
2026-09-14 13:43:09 UTC#307760updateconfirmednews
CG Oncology's Zipalertinib plus chemo hits 14.5-month median PFS in REZILIENT-3 Phase 3 NSCLC trial
2026-09-14 11:34:42 UTC#306862newconfirmednews
CG Oncology's Zipalertinib plus chemo meets primary endpoints in Phase 3 REZILIENT 3 trial for EGFR ex20ins NSCLC
2026-09-14 11:00:00 UTC#306643newconfirmedpress release
Cullinan Therapeutics to host investor event today on Phase 3 REZILIENT3 zipalertinib lung cancer trial data
globenewswireimportance 0.40trust 0.90Cullinan Therapeutics, Inc. +0.30Nadim Ahmed 0Jeffrey Jones 0+2 entities
2026-08-19 23:57:00 UTC#198019newconfirmedpress release
Kuehn Law, PLLC launches investigation into potential fiduciary duty breaches at CG Oncology, Inc. (CGON)
2026-08-17 10:51:00 UTC#184014newconfirmednews
HC Wainwright & Co. maintains $30.00 price target on Cullinan Therapeutics (CGEM)
2026-08-13 10:52:08 UTC#170952newconfirmednews
Cullinan Therapeutics lung cancer drug meets primary endpoint in late-stage clinical trial
2026-08-07 18:48:00 UTC#146931newconfirmednews
RBC Capital maintains Outperform rating on CG Oncology, cuts price target to $79 from $81
2026-08-07 17:05:00 UTC#146478newconfirmednews